322 related articles for article (PubMed ID: 25742187)
1. Understanding the Concept of Health Care-Associated Pneumonia in Lung Transplant Recipients.
Palacio F; Reyes LF; Levine DJ; Sanchez JF; Angel LF; Fernandez JF; Levine SM; Rello J; Abedi A; Restrepo MI
Chest; 2015 Aug; 148(2):516-522. PubMed ID: 25742187
[TBL] [Abstract][Full Text] [Related]
2. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study.
Quartin AA; Scerpella EG; Puttagunta S; Kett DH
BMC Infect Dis; 2013 Nov; 13():561. PubMed ID: 24279701
[TBL] [Abstract][Full Text] [Related]
3. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
Werarak P; Kiratisin P; Thamlikitkul V
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
[TBL] [Abstract][Full Text] [Related]
4. Emerging trends of nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western India.
Bhadade R; Harde M; deSouza R; More A; Bharmal R
Ann Afr Med; 2017; 16(3):107-113. PubMed ID: 28671150
[TBL] [Abstract][Full Text] [Related]
5. Healthcare-Associated Pneumonia and Hospital-Acquired Pneumonia: Bacterial Aetiology, Antibiotic Resistance and Treatment Outcomes: A Study From North India.
Kumar S; Jan RA; Fomda BA; Rasool R; Koul P; Shah S; Khan UH; Qadri SM; Masoodi SR; Mantoo S; Muzamil M
Lung; 2018 Aug; 196(4):469-479. PubMed ID: 29691645
[TBL] [Abstract][Full Text] [Related]
6. The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study.
Chang Y; Jeon K; Lee SM; Cho YJ; Kim YS; Chong YP; Hong SB
J Korean Med Sci; 2021 Oct; 36(41):e251. PubMed ID: 34697926
[TBL] [Abstract][Full Text] [Related]
7. Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit.
Becher RD; Hoth JJ; Rebo JJ; Kendall JL; Miller PR
Surg Infect (Larchmt); 2012 Dec; 13(6):352-9. PubMed ID: 23268613
[TBL] [Abstract][Full Text] [Related]
8. A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy.
Maruyama T; Fujisawa T; Ishida T; Ito A; Oyamada Y; Fujimoto K; Yoshida M; Maeda H; Miyashita N; Nagai H; Imamura Y; Shime N; Suzuki S; Amishima M; Higa F; Kobayashi H; Suga S; Tsutsui K; Kohno S; Brito V; Niederman MS
Clin Infect Dis; 2019 Mar; 68(7):1080-1088. PubMed ID: 30084884
[TBL] [Abstract][Full Text] [Related]
9. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind Hospital, northeastern Thailand.
Reechaipichitkul W; Phondongnok S; Bourpoern J; Chaimanee P
Southeast Asian J Trop Med Public Health; 2013 May; 44(3):490-502. PubMed ID: 24050082
[TBL] [Abstract][Full Text] [Related]
10. Intermediate risk of multidrug-resistant organisms in patients who admitted intensive care unit with healthcare-associated pneumonia.
Lee H; Park JY; Lee T; Lee YJ; Lim HJ; Park JS; Yoon HI; Lee JH; Lee CT; Cho YJ
Korean J Intern Med; 2016 May; 31(3):525-34. PubMed ID: 26968189
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Kaye KS; Udeani G; Cole P; Friedland HD
Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
[TBL] [Abstract][Full Text] [Related]
12. How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?
Bassetti M; Peghin M; Carnelutti A; Righi E
Semin Respir Crit Care Med; 2017 Jun; 38(3):301-310. PubMed ID: 28578554
[TBL] [Abstract][Full Text] [Related]
13. Time to Guideline-Based Empiric Antibiotic Therapy in the Treatment of Pneumonia in a Community Hospital: A Retrospective Review.
Erwin BL; Kyle JA; Allen LN
J Pharm Pract; 2016 Aug; 29(4):386-91. PubMed ID: 25601458
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia.
Liu WD; Shih MC; Chuang YC; Wang JT; Sheng WH
J Microbiol Immunol Infect; 2019 Oct; 52(5):788-795. PubMed ID: 31155463
[TBL] [Abstract][Full Text] [Related]
15. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.
Barbier F; Andremont A; Wolff M; Bouadma L
Curr Opin Pulm Med; 2013 May; 19(3):216-28. PubMed ID: 23524477
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864
[TBL] [Abstract][Full Text] [Related]
17. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.
Pugh R; Grant C; Cooke RP; Dempsey G
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007577. PubMed ID: 26301604
[TBL] [Abstract][Full Text] [Related]
18. Pneumonia in solid organ transplant recipients: a prospective multicenter study.
Giannella M; Muñoz P; Alarcón JM; Mularoni A; Grossi P; Bouza E;
Transpl Infect Dis; 2014 Apr; 16(2):232-41. PubMed ID: 24593292
[TBL] [Abstract][Full Text] [Related]
19. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
[TBL] [Abstract][Full Text] [Related]
20. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.
Maruyama T; Fujisawa T; Okuno M; Toyoshima H; Tsutsui K; Maeda H; Yuda H; Yoshida M; Kobayashi H; Taguchi O; Gabazza EC; Takei Y; Miyashita N; Ihara T; Brito V; Niederman MS
Clin Infect Dis; 2013 Nov; 57(10):1373-83. PubMed ID: 23999080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
